X4 Pharma Q3 Net Loss Narrows to $29.8mln Amid Clinical Trial Progress

X4 Pharmaceuticals reported a Q3 net loss of $29.8 mln, a narrowing from previous quarters. The company is focused on developing therapeutics for rare diseases and immune system dysfunction, with its lead candidate mavorixafor being developed as an oral, once-daily therapy. Two pre-clinical candidates, X4P-003 and X4P-002, are also in development.